Skip to main content

Table 2 Baseline cancer-related characteristics of the 122 RD patients with cancer and the 366 age-, sex-, and cancer-matched controls without RD

From: Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis

  Gastric Colon Lung Breast
  RD (n = 28) Non-RD (n = 83) p RD (n = 23) Non-RD (n = 69) p RD (n = 44) Non-RD (n = 133) p RD (n = 27) Non-RD (n = 81) p
ECOGc             
 ≤1 28 (100.0) 81 (97.6) 1.000b 22 (95.7) 45 (65.2) 0.006b 34 (77.3) 119 (89.5) 0.041a 27 (100.0) 81 (100.0) 1.000b
 ≥2 0 (0) 2 (2.4) 1.000b 1 (4.3) 24 (34.8) 0.006b 10 (22.7) 14 (10.5) 0.041 a 0 (0) 0 (0) 1.000
Charlsond             
 0 16 (57.1) 54 (65.1) 0.501b 8 (34.8) 46 (66.7) 0.025b 22 (50.0) 90 (67.7) 0.047a 18 (66.7) 65 (80.2) 0.188b
 1 5 (17.9) 17 (20.5) 1.000b 8 (34.8) 12 (17.4) 0.090b 12 (27.3) 22 (16.5) 0.127b 4 (14.8) 11 (13.6) 1.000b
 ≥2 7 (25.0) 12 (14.5) 0.246a 7 (30.4) 11 (15.9) 0.141b 11 (22.7) 21 (15.8) 0.180b 5 (18.5) 5 (6.2) 0.117b
Stage             
 I 13 (46.4) 41 (49.4) 0.830b 7 (30.4) 12 (17.4) 0.234b 14 (31.8) 27 (20.3) 0.149b 14 (51.9) 24 (29.6) 0.036a
 II 6 (21.4) 15 (18.1) 0.781b 5 (21.7) 14 (20.3) 1.000b 5 (11.4) 77 (57.9) <0.001 b 10 (37.0) 44 (54.3) 0.120a
 III 1 (3.6) 6 (7.2) 0.677b 4 (17.4) 23 (33.3) 0.190b 6 (13.6) 15 (11.3) 0.788 b 1 (3.7) 6 (7.4) 0.678b
 IV 7 (25.0) 20 (24.1) 1.000b 7 (30.4) 18 (26.1) 0.788b 16 (36.4) 14 (10.5) <0.001 b 2 (7.4) 2 (2.5) 0.260b
 NA 1 (3.6) 1 (1.2) 0.443b 0 (0) 2 (2.9) 1.000b 3 (6.8) 0 (0) 0.015 b 0 (0) 5 (6.2) 0.328b
  1. Data are expressed as number (%)
  2. F female, NA not applicable, RD rheumatic disease
  3. aChi-square test, bFisher’s exact test
  4. cEastern Cooperative Oncology Group (ECOG) performance status
  5. dThe Charlson comorbidity index was adjusted for connective tissue disease and cancer